Genmab A (GMAB) EBT Margin Growth (3y) (2021 - 2025)
Powered by 
Analysis
Genmab A (GMAB) EBT Margin Growth (3y) (2021 - 2025) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | 443.00 |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | -15,548.00 |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | -484.00 |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | 132.00 |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | -2,054.00 |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | 6,691.00 |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | 9,980.00 |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | -2,399.00 |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | -1.89 Mn |
| 10 | Genmab A | 2.23 Bn | 728.64 Mn | 1.07 Bn | -1,509.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | -3,805.00 |
| Sep 30, 2024 | -1,389.00 |
| Jun 30, 2024 | -3,198.00 |
| Dec 31, 2023 | -3,886.00 |
| Sep 30, 2023 | 1,804.00 |
| Jun 30, 2022 | 6,437.00 |
| Dec 31, 2021 | -1,712.00 |